UK Constipation Therapeutics Market Report 2022 to 2030

UK Constipation Therapeutics Market Analysis

$ 3999

UK Constipation Therapeutics Market was valued at $473 Mn in 2022 and is estimated to reach $673 Mn in 2030, exhibiting a CAGR of 4.5% during the forecast period. The constipation therapeutics market is experiencing growth driven by the rising prevalence of constipation worldwide, attributed to factors like aging, sedentary lifestyles, and unhealthy dietary habits, with the expanding elderly population, more prone to chronic conditions, further contributing to this market expansion. Notable participants in this industry include AbbVie, Almirall, Boehringer Ingelheim, Ferring Pharmaceuticals, Johnson & Johnson, Norgine Pharmaceuticals, Pfizer, Recordati, Sanofi, and Takeda Pharmaceuticals.

ID: IN10GLPH314 CATEGORY: Pharmaceuticals GEOGRAPHY: UK AUTHOR: Medha Sansanwal

Buy Now

UK Constipation Therapeutics Market Executive Summary

UK Constipation Therapeutics Market was valued at $473 Mn in 2022 and is estimated to reach $673 Mn in 2030, exhibiting a CAGR of 4.5% during the forecast period.

Constipation is a digestive condition characterized by infrequent, difficult, or hard bowel movements due to slowed transit of stool through the colon, leading to increased water absorption and stool hardening. This condition results from a decrease in the speed at which feces pass through the large intestine. Common symptoms of constipation include straining during defecation, a sensation of incomplete evacuation, abdominal discomfort, and irregular or infrequent bowel habits. Various factors, such as a low-fiber diet, insufficient fluid intake, lack of physical activity, specific medications, and underlying medical issues, can contribute to constipation. Treating constipation often involves lifestyle modifications, dietary changes, increased physical activity, and, when necessary, the use of medications to manage and alleviate symptoms.

Constipation is prevalent among hospitalized patients in the UK, with a notable rate of 55.6%. Approximately 6.5 Mn people in the UK, equivalent to 1 in 10 of the population, struggle with some form of bowel problem. In the general population, constipation's mean prevalence stands at 17.1%, with a median value of 16.6%. Alarmingly, 11% of the UK population either could not identify or were unaware of the symptoms of constipation. These statistics underscore that constipation is a widespread issue in the UK, affecting a substantial portion of the population and emphasizing the need for awareness and effective management strategies.

The rising popularity of mobile apps and devices that offer personalized plans, dietary guidance, and biofeedback training is becoming notable in the management of constipation, providing patients with convenient and accessible tools. The increased accessibility to healthcare professionals through telemedicine services has the potential to enhance diagnosis, treatment adherence, and remote monitoring for constipation, particularly in remote areas where access to healthcare may be limited. Wearables with integrated sensors have the capability to track gut activity, providing real-time feedback to both patients and healthcare providers. This offers valuable insights into bowel function and potential triggers, contributing to a more comprehensive approach to constipation management.

Market Dynamics

Market Growth Drivers

Increasing Aging Population: The number of people aged 85 and over in the UK is increasing rapidly. In 2021, there were over 1.5 Mn people in this age group, and this number is expected to double by 2050. Constipation is more prevalent among the elderly, and as the population ages, there is a higher demand for constipation therapeutics.

Over-the-counter (OTC) Products: The presence of over-the-counter (OTC) constipation remedies and laxatives can stimulate growth in the constipation therapeutics market by offering individuals accessible self-treatment options, thereby enhancing market demand.

Lifestyle Factors Impacting Prevalence: Lifestyle factors, including sedentary habits and dietary choices, contribute significantly to the widespread occurrence of constipation, further boosting the demand for therapeutic interventions in the market.

Market Restraints

Side Effects and Safety Concerns: Some constipation therapeutics may have side effects or safety concerns, leading to hesitancy among patients and healthcare providers in adopting certain treatments.

Patient Adherence: Compliance and adherence to prescribed constipation treatments can be challenging, affecting the overall effectiveness of the therapeutics and potentially limiting market growth.

Alternative Therapies: The availability and use of alternative therapies, such as dietary changes, herbal remedies, or lifestyle modifications, may compete with traditional constipation therapeutics, impacting market demand.

Healthcare Policies and Regulatory Landscape

In the UK, the management of healthcare policies and regulatory oversight for therapeutic drugs is primarily conducted by the Medicines and Healthcare Products Regulatory Agency (MHRA), an executive agency under the Department of Health and Social Care. The MHRA plays a crucial role in ensuring the safety, effectiveness, and quality of medications through activities such as granting marketing authorization, approving clinical trials, and maintaining continuous pharmacovigilance. Additionally, the National Institute for Health and Care Excellence (NICE) provides guidance on the clinical and cost-effectiveness of treatments, influencing the pricing and reimbursement of drugs. The dynamic interaction between these regulatory bodies shapes the landscape governing the development, approval, and accessibility of therapeutic drugs in the UK.

Competitive Landscape

Key Players

AbbVie
Almirall
Boehringer Ingelheim
Ferring Pharmaceuticals
Johnson & Johnson
Norgine Pharmaceuticals
Pfizer
Recordati
Sanofi
Takeda Pharmaceuticals

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

UK Constipation Therapeutics Market Segmentation

By Therapeutic

Laxatives
Chloride Channel Activators
Peripherally Acting Mu-Opioid Receptor Antagonists
GC-C Agonists
5-HT4 Receptor Agonists

By Disease

Chronic Idiopathic Constipation
Irritable Bowel Syndrome with Constipation
Opioid-Induced Constipation

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.